Document is current

Any future updates will be listed below

Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

Crossref DOI link: https://doi.org/10.1186/s12967-018-1460-4

Published Online: 2018-04-03

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark